Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD 4)

Share this content:
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD 4)

Sponsors and Collaborators
Novartis Pharmaceuticals

Contact
Novartis Pharmaceuticals
+1-862-778-8300

Principal Investigator
Novartis Pharmaceuticals

ClinicalTrials.gov Identifier
NCT01491672

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters